Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ukraine: Russians abduct 50 Ukrainians from border village in Sumy - 2German men need approval for stays abroad under military service law
- 3Blood pressure drug recalled for possible cross-contamination
- 4In a scientific first, biologists recorded a wild wolf potentially using tools
- 5Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
- Which European countries have mandatory or voluntary military service
- 'Inflaming tensions': Bedouin mayor slams Ben-Gvir's unauthorized visit after meeting cancellation
- One of the best meteor showers of the year peaks at the worst possible time this week
- ACA subsidies latest: Making sense of what's happening with health care after Republicans revolt, forcing a vote on funding extension
- Vote In favor of Your Favored Video Conferencing Administration
- Artemis 2 astronauts fly around the moon in record-breaking lunar loop by NASA
- Material of Innovativeness: A Survey of \Releasing Your Imaginative Potential\ Online Workmanship Course
- Figure out How to Take part in Open Conversations Around 5G Pinnacles
- The Solution to Individual budget: Dominating Cash The board
